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Abstract
Background: Hepatitis B virus co-infection with other strains of  viral hepatitis is associated with increased risk of  liver cirrhosis 
and hepatic decompensation.
Objectives: This is a prevalence study that assessed the genetic diversity of  chronic hepatitis B patients and coinfection.
Methods: Chronic hepatitis B patients enrolled in this study were tested for antibodies of  other hepatitis viruses using ELISA 
kits. Patient clinical profiles were collected and partial genes of  HBV, HCV, and HEV were amplified, sequenced, and analyzed 
using phylogenetic analysis. The associations between variables were determined using the chi-squared test. 
Results: Of  the 82 patients recruited for this study, 53.7% were non-cirrhotic, 22.0% cirrhotic, 20.7% acute flare and 3.7% he-
patocellular carcinoma. Majority (58%) of  patients had a high level of  ALT (≥34 U/L). Sequence analysis showed HBV (63.9%) 
belonged to genotype B, HEV belonged to genotype 4 while HCV belonged to genotype 3a and the genotypes were found to 
be significantly associated with the clinical stage of  the patients (χ2=56.632; p<0.01). Similarly, Hepatitis B e antigen was also 
found to be significantly associated with the clinical stage of  infection (χ2=51.952; p<0.01).
Conclusion: This study revealed that genetic diversity was found to have a significant impact on the severity of  infection. 
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Introduction
Hepatitis B virus (HBV) causes a globally endemic viral 
infection with an estimated 240 million chronically in-
fected patients. Hepatitis B causes an annual mortality 
of  780,000 of  which 650,000 deaths occur in chronically 
infected patients secondary to liver cirrhosis and cancer; 
the remaining 130,000 deaths are a result of  acute hepa-
titis B infection. In Malaysia, 1 million people chronically 
infected with hepatitis B and 453,700 people were living 
with HCV infection. However, Chronic hepatitis B ac-
counts for more than 80% of  the hepatocellular carci-
noma (HCC) cases seen in Malaysia, and is the 3rd most 
common malignant neoplasm and among the 10 leading 
causes of  death.1 Hepatocellular carcinoma (HCC) is one 
of  the most common cancers globally and is highly relat-
ed to viral hepatitis, especially hepatitis B and C2. Hep-
atitis B genome diversity is globally influenced by both 
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phenotypic and genotypic variability. Phenotypic variabil-
ity often develops in the presence of  selective pressure 
mounted by the immune system of  the host during vac-
cination or therapy. Genotypic variability often evolves in 
the absence of  such selective pressure.
Hepatitis C virus (HCV) is an important underlying fac-
tor in the development of  liver diseases and contributes 
to 25% of  liver cancer cases globally3.  The prevalence of  
hepatitis C virus in Asia has been reported to be 2%, with 
high genetic variability4,5.  The predominant genotype 
in SouthEast Asia is genotype 6, while genotypes 1 – 3 
are distributed globally6-8. Hepatitis D virus (HDV), con-
versely, is an unusual single stranded RNA virus that is 
devoid of  an envelope protein and depends on HBV for 
its enveloped protein9.  The predominant HDV genotype 
in Asia is genotype 2, most especially in East Asia, while 
genotype 1 has a global distribution; the remaining six 
genotypes are distributed in other geographical areas10. 
Hepatitis D virus has also been reported as an important 
cause of  acute and chronic liver disease in several regions 
of  the world11. 
Epidemics of  hepatitis E virus (HEV) have been report-
ed in Central and SouthEast Asia, the Middle East, Af-
rica and other parts of  the world12.  Its transmission is 
predominantly feco-oral and can be zoonotic. HEV is a 
common cause of  acute viral hepatitis globally13.  HEV is 
associated with the development of  acute-on-chronic liv-
er failure and increased mortality among chronic liver dis-
ease patients14.  Hepatitis C, D, and E, when present as a 
co-infection or super-infection in a chronic HBV patient, 
lead to more severe disease with higher mortality than in 
HBV mono-infection15,16.  However, little is known on 
the effect of  HBV co-infection with other viral hepati-
tis strains, most especially in Malaysia. As such, in this 
study, we assessed the prevalence of  HBV, HCV, HEV 
genotypes in patients with HBV infection and the pre-
dominant co-infection with other hepatitis viruses and 
their different genotypes in relation to the clinical stage 
of  infection.
 
Materials and methods 
Study design
This was an analytical cross-section, involving 82 patients 
with treatment naïve chronic hepatitis B infection at the 
time of  their first visit to the hepatology clinic.
Patients recruitments
Patients were recruited consecutively from the Hepatol-
ogy Department, Selayang Hospital, Selangor which is a 
tertiary hepatology referral Centre in Malaysia.
 
Sample and data collection
Purposive (judgmental) sampling will be used for this 
study in which subjects will be picked on the basis of  spe-
cific clinical and biochemical characteristics as determined 
by the physician. Blood samples were collected at the 
Hepatology Department at Hospital Selayang, Selangor, 
Malaysia, between May 2015 and May 2016. In total, 82 
blood samples were collected from patients with chronic 
hepatitis B infection at the time of  their initial presenta-
tion to the clinic. Sample size was determined using the 
sample size formula for estimating minimum sample size 
in cross-sectional study as described by Daniel W. Biosta-
tistics: A Foundation for Analysis in the Health Sciences, 
7th edR Wiley. New York. 1999. The patients’ plasma was 
separated from the blood immediately after collection, 
frozen and transported on ice to the Laboratory of  Clin-
ical and Molecular Virology at Universiti Putra Malaysia 
for further analysis. Hospital Selayang is a national tertia-
ry referral center which specializes in managing patients 
with acute or chronic liver diseases. All samples were free 
of  human immunodeficiency virus. All leftover samples 
were archived and anonymized. Patient biodata, clinical 
information such as presence of  jaundice, easy fatigability 
and pruritus laboratory information such as liver func-
tion test and serum protein was collected via a proforma 




Ethical approval to conduct this study was obtained from 
the Ministry of  Health Malaysia Medical Research and 
Ethics Committee (KKM/NIHSEC/ P15-63) as well as 
the Universiti Putra Malaysia Human Research Ethics 
Committee (UPM/TNCPI/RMC/JKEUPM/1.4.18.1/
F1). Consent was obtained from the respective patients 
who volunteered for the study by the attending physician.
 
Serology screening 
Plasma samples from all patients were tested for hepati-
tis B surface antigen (HBsAg) using an ELISA kit (DRG 
International Inc. New Jersey, USA). Further tests for 
antibodies against hepatitis B surface antigen (anti-HBs), 
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hepatitis B e antibody (anti-HBe), hepatitis B e antigen 
(HBeAg) and hepatitis B core antigen (IgG and IgM an-
ti-HBc)  were carried out on all 82 plasma samples. All 
plasma samples were screened for hepatitis C, D and E 
virus antibodies (anti-HDV, anti-HCV and anti-HEV) 
using ELISA kits (Novatein Biosciences, Woburn, MA), 
and for hepatitis E virus antibodies (IgG and IgM) (Wan-
tai Bio-pharm., Beijing, China) according to manufactur-
er’s instructions.
 
Extraction of  HBV DNA
Hepatitis B viral DNA was extracted from plasma (200 
µl) using a QIAamp DNA blood mini kit according to the 
manufacturer’s instructions (Qiagen Hilden, Germany). 
Briefly, 20 µl of  proteases was put into a 1.5 ml tube after 
which 200 µl of  plasma was added, followed by AL buffer 
(cell lysing buffer). The mixture was then vortexed and 
incubated for 10 minutes at 56ºC, after which 200 µl of  
ethanol was added in order to enhance the precipitation 
of  DNA trapped in the column. The trapped DNA was 
then washed with wash buffer AW1, followed by AW2 to 
eliminate impurities. Finally, the DNA was eluded with 
40 µl of  elution buffer then stored at -20ºC until further 
analysis.
 
HBV DNA amplification and sequencing
Two sets of  published primers were used for amplifica-
tion of  the hepatitis B small S gene from the stored DNA 
samples. The amplification was performed using nested 
PCR, in which extracted HBV DNA was used in the first 
round PCR, while the product of  the first round was used 
as the template for the second round PCR. Both PCR 
amplification was done as described previously17.  The 
products of  amplification were analyzed using gel elec-
trophoresis with a 1.5% agarose gel (Seakem LE, USA). 
Electrophoresis was performed at 80 V and 400 A for 
45 min (Bio-Rad, USA). PCR products were visualized 
using a Gel Doc XR imager (Bio-Rad, USA) and the 
product size was determined by comparison to a DNA 
molecular marker (GeneDireX). The products were se-
quenced commercially by integrated DNA Technologies 
(IDT, Gemini Singapore). All our Malaysian sequences 
were deposited in GenBank under the accession numbers 
KX670217-KX670241 and KX682284-KX682340 for 
genotypes C and B, respectively.
 
RNA extraction
Viral RNA was extracted from hepatitis C and E sero-
positive plasma samples using a high purity viral RNA ex-
traction kit according to the manufacturer’s instructions 
(Roche, Germany). Briefly, 400 µl of  binding buffer sup-
plemented with poly A was put in a 1.5 ml tube and then 
200 µl of  plasma was added, thoroughly mixed and trans-
ferred into a high purity filter assembly. The mixture was 
incubated for 10 minutes at room temperature and cen-
trifuged for 15 seconds at 800 x g. The flow-through was 
discarded along with the collection tube and the upper 
filter tube was re-assembled with a new collection tube. 
The final elution step was performed by the addition of  
50 µl of  elution buffer into the upper reservoir and cen-
trifugation at 8000 x g for 1 min. The RNA sample was 
aliquoted, tested for purity and kept at -70oC until further 
use. 
 
RNA purity and concentration
The extracted RNA was subjected to purity and concen-
tration checks. The optical density of  the RNA sample 
was measured using a Nanodrop spectrophotometer ac-
cording to the manufacturer’s instructions. Absorbance 
ratios at A260/280 were obtained to determine the con-
centration and purity of  the RNA. The quality of  RNA is 
considered good when the A260/A280 ratio is within the 
range of  1.9 to 2.1.
 
RNA amplification and sequencing
Viral RNA from both HCV and HEV were amplified by 
reverse transcriptase polymerase chain reaction (RT-PCR) 
using the Monster script reverse transcriptase kit (Epicen-
ter Technologies Corp., Chicago, IL, USA) according to 
manufacturer’s guide. Briefly, 0.5 ml PCR tubes contain-
ing 10 µl of  viral RNA sample, 2 µl of  random primers 
and 3 µl of  RNase-free water were incubated at 65ºC for 
1 min in a thermal cycler (Bio-Rad Laboratories, Inc. Cal-
ifornia USA). The heated samples were placed on ice im-
mediately for 1 min. Then 4 µl of  cDNA premix and 1 µl 
of  MonsterScript reverse transcriptase were added. The 
tube was mixed gently and incubated for 5 min at 37ºC, 
then heated at 45ºC for 5 min, then incubated for 40 min 
at 60ºC in a thermal cycler (Bio-Rad Laboratories, Inc. 
California USA). The reaction was terminated by heating 
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at 90ºC for 5 min, after which the samples were cooled 
on ice for 1 min. The cDNA was extracted by brief  cen-
trifugation for 1 min, and then samples were stored at 
-30ºC until used. Samples were amplified using published 
primers targeting HEV-ORF2, as described previously18. 
Similarly, HCV RNA was also amplified using published 
primers targeting HCV- NS5B.19  The PCR products for 
both HEV and HCV were analyzed using gel electropho-
resis and visualized using a Gel Doc XR imager (Bio-Rad, 
USA). The amplified products were purified using the 
GF-1 PCR clean-up kit (Vivantis Technologies, USA) ac-
cording to the manufacturer’s instructions. The purified 
fragments and PCR products were sequenced commer-
cially by integrated DNAT (IDT, Gemini Singapore). All 
our Malaysian HCV and HEV isolate sequences were de-
posited in GenBank under accession numbers KX449132 
and KX426575-KX426582, respectively.
 
Diversity and phylogenetic analysis
Molecular Evolutionary Genetics Analysis version 7 
(Mega7) software  was used for sequence alignment via 
Clustal W. Phylogenetic analysis was done based on the 
Kimura two-parameter model inferred by the maximum 
likelihood method with the variation rate among gene 
sites modeled with a gamma distribution (G). Reference 
sequences were selected from the GenBank database 
(http://www.ncbi.nih.gov). All our sequences were geno-
typed, sub-genotyped and serotyped by aligning with the 
S-gene, NS5B and ORF2 reference sequences of  estab-
lished genotypes, sub-genotypes and serotypes, respec-
tively, from GenBank. The evolutionary history of  the 
sequenced was also inferred by maximum likelihood.
 
Results
In this study, a total of  82 chronically infected patients 
were recruited from May 2015 to May 2016, of  which 
59.8% (49/82) were male and 40.2% (33/82) were fe-
male. The distribution according to ethnicity was 32.9% 
(27/82) Malay, 62.2% (51/82) Chinese, 3.7% (3/82) In-
dian and 1.2% (1/82) Orang Asli. Half  (41/82) of  the 
patients were older than 50 year of  age and only 11% 
(9/82) were below 30 years of  age; the remaining 39% 
(32/82) of  patients were between 30 and 49 years of  
age. The patients recruited for this study were classified 
into four clinical stages; non-cirrhotic (53.7%), cirrhotic 
(22.0%), acute flare (20.7%) and hepatocellular carcino-
ma (3.7%). All plasma samples were positive for HBsAg, 
IgG anti-HBc, and the negative IgM anti-HBc. Majority, 
i.e. 52.4% (43/82) was positive for HBeAg. Hepatitis B e 
antigen was found to be significantly associated with the 
clinical stage of  infection (χ2=51.952; p<0.01). Hepatitis 
E virus IgG was found to be positive in 8 of  the samples 
while Hepatitis C virus IgG positive in only one sample 
and both were negative for IgM.
 
The viral hepatitis virus that were detected among the 
chronic hepatitis B patients are hepatitis C and E and 
the rate of  the co-infection was found to be 9.8% (8/82) 
for HBV+HEV, and  1.2% (1/82) for HBV+HCV All 
samples were tested negative for HDV while, greater part 
of  them, 89% (73/82) present with hepatitis B mono-in-
fections. Liver function tests revealed that the majority 
(58%) of  patients had an alanine aminotransferase (ALT) 
level (≥34 U/L). Physical examinations showed jaundice 
as the most frequent clinical symptom, followed by easy 
fatigability. The Pearson chi-squared test revealed a strong 
positive correlation between the clinical stage of  infec-
tion and the level of  aspartate aminotransferase (AST) at 
p<0.01 and jaundice (p<0.01). Likewise, alanine amino-
transferase (ALT) was found to correlate moderately with 
clinical condition (p<0.01), as well as serum total biliru-
bin (p<0.01). The total protein and albumin correlated 
negatively with the severity of  infection (Table 1).
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Table 1: Clinical stage of infection (cirrhotic, non-cirrhotic, hepatocellular  
carcinoma and acute flare) correlated with clinical and laboratory findings 
 
 Clinical profile 
  
Clinical stage Pearson correlation 
      
Pearson’s r P-value       
  
        
Past medical and social history    0.119 0.289       
Serum bilirubin (µmol/l) 0.563** 0.000       
Total protein (g/l) -0.390** 0.001       
Albumin (g/l) -0.562** 0.000       
ALT (U/l)    0.483** 0.000       
AST (U/l)    0.597** 0.000       
Jaundice    0.681** 0.000       
Fibro scan    0.13 0.401       
Easy fatigability    0.640** 0.000       
Pruritus    0.373** 0.001       
Platelet count (x109 g/l)    0.015 0.901       
            
           
U/L=units per liter; g/l=gram per liter; **significant correlation at 0.01 (two-tailed) 
µmol/l=micromoles per liter; (-) =negative correlation 
The hepatitis B virus DNA results revealed the amplifica-
tion of  the targeted small S region of  the surface protein, 
which was further confirmed by the sequencing results. 
The HBV sequences of  the Malaysian isolates exhibited 
99% homology with identity ranging from 90 to 100%. 
Phylogenetic analysis of  the Malaysian HBV isolated re-
vealed that the majority, i.e. 69.5% (57/82) of  the isolates, 
were grouped together in a cluster with genotype B; the 
remaining 30.5% (25/82) formed a cluster with genotype 
C (Fig 1). 
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Figure 1: Malaysian hepatitis B virus isolates genotyping  
Phylogenetic tree.Small S gene (656 bp) of the HBsAg was used to  
generate the tree. The local isolates (red dots) are separated into two  
distinct clusters corresponding to genotypes B and C. The alphabet A-H  
indicates genotypes. Sequences without dot are the reference sequences. 
 HBV AB073830 B
 KX682328 HBV UPM67B
 KX682323 HBV UPM57B
 KX682321 HBV UPM54B
 KX682315 HBV UPM47B
 KX682303 HBV UPM34B
 KX682296 HBV UPM22B
 KX682293 HBV UPM19B
 KX682289 HBV UPM12B
 KX682286 HBV UPM7B
 KX682284 HBV UPM2B
 KX682288 HBV UPM9B
 KX682291 HBV UPM17B
 KX682295 HBV UPM21B
 KX682310 HBV UPM42B
 KX682318 HBV UPM50B
 KX682326 HBV UPM62B
 KX682340 HBV UPM88B
 KX682309 HBV UPM41B
 KX682313 HBV UPM45B
 KX682316 HBV UPM48B
 KX682322 HBV UPM56B
 KX682327 HBV UPM63B
 KX682333 HBV UPM78B
 HBV AY033073 B
 KX682311 HBV UPM43B
 KX682317 HBV UPM49B
 KX682325 HBV UPM61B
 KX682330 HBV UPM71B
 KX682332 HBV UPM77B
 KX682337 HBV UPM85B
 KX682339 HBV UPM87B
 HBV AB033554 B
 HBV AB073853 B
 KX682301 HBV UPM31B
 KX682304 HBV UPM35B
 KX682306 HBV UPM37B
 KX682285 HBV UPM6B
 KX682290 HBV UPM16B
 KX682294 HBV UPM20B
 KX682300 HBV UPM29B
B
 KX670222 HBV UPM11C
 KX670224 HBV UPM14C
 KX670219 HBV UPM4C
 KX670217 HBV UPM1C
 KX670223 HBV UPM13C
 KX670237 HBV UPM73C
 KX670241 HBV UPM81C
 HBV X75656 C
 KX670238 HBV UPM74C
 KX670240 HBV UPM79C
 KX670233 HBV UPM59C
 KX670230 HBV UPM38C
 KX670227 HBV UPM24C
 HBV AY066028 C
 KX670218 HBV UPM3C
 KX670220 HBV UPM5C
 KX670221 HBV UPM10C
 KX670225 HBV UPM15C
 KX670235 HBV UPM66C
 KX670239 HBV UPM75C
 KX670231 HBV UPM53C
 KX670228 HBV UPM26C
 HBV AF223960 C
 KX670226 HBV UPM23C
 KX670229 HBV UPM33C
 KX670232 HBV UPM58C
 KX670234 HBV UPM65C
 KX670236 HBV UPM69C
C
 HBV AJ309371 A
 HBV AY161138 A A
 HBV AF241408 G
 HBV AF241407 G G
 HBV X75657 E
 HBV AB074845 E E
 HBV AB090270 D
 HBV AY161159 D
 HBV GQ205377 D
D
H HBV AY090460 H
 HBV AF223963 F
 HBV AB036908 F F
0.01
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Figure 2: HBV genotype B sub-genotyping of the local isolates  
(Red dots) using nucleotide of the small S gene (656 bp) of the HBsAg.  
Local HBVisolates formed clusters with the reference subtypesB4,  
B2 and B2a (highlighted in red). Sequences without dot are the  
reference sequences. 
serotype, while the remaining 22.81% (13/57) formed a 
cluster with the Ba sub-type (Fig 2) and ayw1 serotype 
(Fig 3), which specifically dominates in Asia and is usually 
referred to as “B Asia”. 
Further analysis showed that HBV genotype B was 
grouped into three sub-types, with the majority, i.e. 
64.91% (37/57), belonging to B2 sub-type and serotype 
adw2; 12.28% (7/57) were of  the B4 sub-type and ayw1 
 KX682340 HBV UPM88B
 HBV GU357842 B2a
 KX682334 HBV UPM80B
 KX682326 HBV UPM62B
 KX682318 HBV UPM50B
 KX682314 HBV UPM46B
 KX682310 HBV UPM42B
 KX682305 HBV UPM36B
 KX682302 HBV UPM32B
 KX682298 HBV UPM27B
 KX682295 HBV UPM21B
 KX682291 HBV UPM17B
 KX682288 HBV UPM9B
 KX682284 HBV UPM2B
 HBV GU815763 B2a
 HBV GU815758 B2
 HBV GU815769 B2
B2a
 HBV KX067736 B2
 KX682287 HBV UPM8B
 KX682289 HBV UPM12B
 KX682293 HBV UPM19B
 KX682296 HBV UPM22B
 KX682297 HBV UPM25B
 KX682299 HBV UPM28B
 KX682303 HBV UPM34B
 KX682307 HBV UPM39B
 KX682315 HBV UPM47B
 KX682320 HBV UPM52B
 KX682323 HBV UPM57B
 KX682324 HBV UPM60B
 KX682328 HBV UPM67B
 KX682329 HBV UPM68B
 KX682331 HBV UPM72B
 KX682338 HBV UPM86B
 HBV KR077124 B2
 HVB AY738934 B2
 HBV JQ801514 B2
 HBV AB073825 B2
 HBV KC774399 B2
 HBV JN604122 B2
 HBV KX067283 B2
 KX682309 HBV UPM41B
 KX682313 HBV UPM45B
 KX682322 HBV UPM56B
 KX682327 HBV UPM63B
 KX682333 HBV UPM78B
B2
 HBV AP011085 B3
 HBV M54923 B3
 HBV AB033555 B3
 HBV AB033554 B3
B3
 HBV AB100695 B4
 HBV AB073835 B4
 HBV AY033072 B4
 HBV AY033073 B4
 KX682311 HBV UPM43B
 KX682317 HBV UPM49B
 KX682325 HBV UPM61B
 KX682330 HBV UPM71B
 KX682332 HBV UPM77B
 KX682337 HBV UPM85B
 KX682339 HBV UPM87B
B4
 HBV AB073858 B1
 HBV AB073852 B1 B5
 HBV D50521 B1
 HBV AB073849 B1 B1
0.002
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Figure 3: HBV genotype B serotyping of the local isolates (Red dots)  
using nucleotide of the small S gene (656 bp) of the HBsAg. Local genotype  
B HBVisolates formed two clusters with the reference serotypes ayw1 and  
adw2 (highlighted in red). Sequences without dot are the reference sequences. 
The Ba sub-type is a recombination of  the B and C sub-
types. HBV genotype C isolates were phylogenetically re-
lated to C2 and serotype ayr in a major cluster containing 
88% (22/25) of  isolates, while the remaining 12% (3/25) 
formed a different cluster and were phylogenetically close 
to C4 (Fig 4) and serotype adrq (Fig 5).
 KX682340 HBV UPM88B
 HBV GU357842 adw2
 KX682334 HBV UPM80B
 KX682326 HBV UPM62B
 KX682318 HBV UPM50B
 KX682314 HBV UPM46B
 KX682310 HBV UPM42B
 KX682305 HBV UPM36B
 KX682302 HBV UPM32B
 KX682298 HBV UPM27B
 KX682295 HBV UPM21B
 KX682291 HBV UPM17B
 KX682288 HBV UPM9B
 KX682284 HBV UPM2B
 KX682331 HBV UPM72B
 KX682324 HBV UPM60B
 KX682315 HBV UPM47B
 KX682303 HBV UPM34B
 KX682292 HBV UPM18B
 KX682286 HBV UPM7B
 KX682296 HBV UPM22B
 KX682307 HBV UPM39B
 KX682320 HBV UPM52B
 HBV AB073827 adw2
 KX682289 HBV UPM12B
 KX682297 HBV UPM25B
 KX682312 HBV UPM44B
 KX682321 HBV UPM54B
 KX682328 HBV UPM67B
 KX682336 HBV UPM84B
 HBV AF121244 adw2
 HBV AB073830 adw2
 KX682309 HBV UPM41B
 KX682313 HBV UPM45B
 KX682316 HBV UPM48B
 KX682322 HBV UPM56B
 KX682327 HBV UPM63B
 KX682333 HBV UPM78B
 KX682301 HBV UPM31B
 KX682304 HBV UPM35B
 KX682306 HBV UPM37B
 KX682285 HBV UPM6B
 KX682290 HBV UPM16B
 KX682294 HBV UPM20B
 KX682300 HBV UPM29B
adw2
 HBV AB073835 ayw1
 HBV AY033072 ayw1
 KX682311 HBV UPM43B
 KX682317 HBV UPM49B
 KX682325 HBV UPM61B
 KX682330 HBV UPM71B
 KX682332 HBV UPM77B
 KX682337 HBV UPM85B
 KX682339 HBV UPM87B
ayw1
 HBV AB048705 ayw3
 HBV AB048704 ayw3
 HBV X75665 adrq
 HBV X75656 adrq
 HBV AF223955 adr
 HBV AF223955 ayr
 HBV X75667 ayr
 HBV AF068756 adr
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Figure 4: HBV genotype C virus sub-genotyping of the local isolates 
(Red dots) using nucleotide sequences of the small S gene (656 bp) of the HBsAg.  
The local isolates formed two clusters of subtypes C2 (red) and C1 (blue).  
C1-C4: subtypes. Sequences without dot are the reference sequences 
 KX670235 HBV UPM66C
 KX670239 HBV UPM75C
 KX670231 HBV UPM53C
 KX670228 HBV UPM26C
 HBV AB074756 C2
 HBV AF223955 C2
 HBV AB074755 C2
 HBV AF068756 C2
 KX670226 HBV UPM23C
 KX670229 HBV UPM33C
 KX670232 HBV UPM58C
 KX670234 HBV UPM65C
 KX670236 HBV UPM69C
 KX670218 HBV UPM3C
 KX670220 HBV UPM5C
 KX670221 HBV UPM10C
 KX670225 HBV UPM15C
 KX670222 HBV UPM11C
 KX670224 HBV UPM14C
 KX670219 HBV UPM4C
 KX670217 HBV UPM1C
 KX670233 HBV UPM59C
 KX670227 HBV UPM24C
 KX670230 HBV UPM38C
 KX670238 HBV UPM74C
 KX670240 HBV UPM79C
C2
 HBV X75656 C3
 HBV X75665 C3
 HBV AF208876 C3
C3
 KX670223 HBV UPM13C
 KX670237 HBV UPM73C
 KX670241 HBV UPM81C
 HBV KT364752 C1
 HBV GQ261931 C1
C1
 HBV AB048705 C4
 HBV AB048704 C4 C4
0.005
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Figure 5: HBV genotype C virus sero-typing of the local isolates (Red dots)  
Using nucleotide sequences of the small S gene (656 bp) of the HBsAg.  
The majority of the local isolates belonged to the ayr (Blue) and only three of the  
isolates belonged to the adeq+ (red). Sequences without dot are the references sequences. 
 KX670235 HBV UPM66C
 KX670239 HBV UPM75C
 KX670231 HBV UPM53C
 KX670228 HBV UPM26C
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 KX670226 HBV UPM23C
 KX670229 HBV UPM33C
 KX670232 HBV UPM58C
 KX670234 HBV UPM65C
 KX670236 HBV UPM69C
 KX670218 HBV UPM3C
 KX670220 HBV UPM5C
 KX670221 HBV UPM10C
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 KX670222 HBV UPM11C
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The hepatitis C virus that was found to be co-infected 
with HBV in this study was phylogenetically related to 
isolate D17763 from Japan and belonged to genotype 
3 subtype a, forming a cluster with other reference iso-
lates of  similar genotypes and subtypes (Fig 6). Similarly, 
hepatitis E virus (HEV) co-infected with HBV phyloge-
netically formed a single cluster with isolates from China 
(AB108537), isolated from sporadic HEV infection cases 
and one from Japan (AB220974) isolated from a fulmi-
nant acute self-limiting HEV infection; this cluster be-
longs to genotype 4 (Fig 7). Hepatitis B genotype B was 
found to be co-infected with HCV genotype 3a, while 
HEV genotype 4 was found to be co-infected with both 
genotypes B and C of  HBV. The hepatitis B genotype was 
found to be significantly (χ2=56.632; p<0.01) associated 
with the clinical stage of  infection as shown in table 2.
 
 
Figure 6: Hepatitis C virus genotype and subtype inferred by phylogenetically 
using HCV capsid NS5B nucleotide sequence. The local isolate (Red dot) form  
a cluster with genotype 3 subtype a (3a) as highlighted in red. Sequences 
without dot are the reference sequences. 
 HCV D49374 3b
 HCV JQ065709 3b
 HCV KJ470616 3b
 HCV JX227955 3i
 HCV JX227956 3i
 HCV JF735123 3g
 HCV JX227954 3g
 HCV KX449132 UPM 2
 HCV D17763 3a
 HCV KJ470614 3a
 HCV GU814263 3a
 3a
 HCV JF735121 3h
 HCV JF735126 3h
Genotype 3
 HCV D84262 6b
 HCV EU246930 6a
 HCV EU246932 6e
 HCV DQ835760 6f
 HCV EF424629 6c
 HCV D84263 6d
Genotype 6
 HCV FJ462435 4b
 HCV FJ462432 4g
 HCV JX227971 4g
 HCV EU392171 4k
 HCV FJ462438 4k
 HCV EU392174 4f
 HCV EU392169 4f
 HCV DQ988074 4a
 HCV AB795432 4a
 HCV FJ462436 4c
 HCV DQ418786 4d
 HCV EU392172 4d
 HCV FJ462437 4d
Genotype 4
 HCV AY651061 1c
 HCV EU781828 1b
 HDV KC248199 1h
 HCV EF407457 1a
 HCV JQ791196 1a
 HCV KC248194 1e
 HCV AM910652 1g
Genotype 1
 HCV AF064490 5a
 HCV Y13184 5a
Genotype 5
 HCV JX227965 2c
 HCV AF169004 2a
 HCV JF735117 2d
 HCV JF735120 2e
 HCV DQ155561 2i
 HCV JF735115 2r
 HCV KC844042 2f
Genotype 2
Genotype 7 HCV EF108306 7a
0.05
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Figure 7: Hepatitis E virus genotyping using viral capsid OFR2 nucleotide 
sequences in generating the phylogenetic tree. The red dots indicate local  
isolates which forms cluster with genotype 4 (highlighted in red). G1-G4  
indicates genotypes. Sequences without dot are the reference sequences. 
 HEV-DQ450072 China Swine
 HEV-JQ993308 China Swine
 HEV HSA KX426575
 HEV-JF915746 China Swine
 HEV-AB238522 Japan Swine
 HEV-EF570133 China Swine
 HEV HSA KX426580
 HEV HSA KX426576
 HEV-AB602440 Japan Boar
 HEV HSA KX426577
 HEV HSA KX426578
 HEV HSA KX426579
 HEV HSA KX426581
 HEV HSA KX426582
 HEV AB220974 G4
 HEV AB074915 G4
 HEV AB097812 G4
G4
 HEV-EU676172 China Swine
 HEV-AY723745 India swine
 HEV-EU366959 China Swine
 HEV M73218 G1
 HEV D10330 G1
 HEV AF051830 G1
 HEV X98292 G1
G1
 HEV M74506 G2
 HEV AF172999 G2 G2
 HEV AB248520 G3
 HEV-AF455784 Kyrgyzstan swine
 HEV AP003430 G3
 HEV AF060669 G3
 HEV AF060668 G3
 HEV AB074920 G3
 HEV AB074918 G3
G3
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Table 2: Clinical stage of infection associated with hepatitis genotypes 
 
Clinical stage of 
infection 








B (n=57) C (n=25) 3a 4 
Non-cirrhotic chronic 
hepatitis B 
68.4 (39) 20.0(5) 0 37.5 (3) 
Cirrhotic chronic hepatitis 
B 
1.8 (1) 68 (17) 0 37.5 (3) 
Hepatitis B acute flare 29.8 (17) 0 100 (1/1) 12.5 (1) 
Hepatitis Bhepatocellular 
carcinoma 
0 12 (3) 0 12.5 (1) 
             Total (%) 100 100 100 100 
The numbers in parenthesis (n) indicate frequency; positive (+); negative (-); percentage (%)*Pearson  
chi-squared 56.632; p-value 0.000; B: genotype B; C: genotype C; 3a: Subtype; 4: Subtype 4  
Discussion 
In this study, we determined the proportion of  hepatitis 
B co-infections and the clinical and genetic diversities of  
HBV, HCV and HEV. The results showed 9.8% and 1.2% 
hepatitis B co-infection with HEV and HCV, respectively, 
among Malaysian chronic hepatitis B patients. Hepatitis B 
and C co-infection was found to be very low among the 
Malaysian chronic hepatitis B infection patients at only 
1.2%. This is far lower than what was reported in India 
(12.3%)20 and Taiwan (8%)21, and closely related to what 
was reported (2.7%) in Santo Antonio General hospital 
in Portugal22.  On the other hand, the rate of  hepatitis E 
co-infection with hepatitis B reported in this study was 
lower than what was reported in Chennai, India (6.25%)23 
and Bangladesh (18.1%)24, and is much higher in Egypt 
(56.7%)25. The results of  our co-infected patients show 
increased levels of  total bilirubin and liver enzymes with 
low albumin levels and normal platelet counts. This is in 
contrast to what was reported in a previous study sug-
gesting that chronic hepatitis B infection may be inac-
tive in the presence of  HEV infection26.  Similarly, HCV 
co-infection in chronic hepatitis B patients has been relat-
ed to a poor prognosis and the development of  cirrhosis 
or HCC27. This was confirmed by the present study, in 
which the only patient that was found to have an HCV 
super-infection presented with hepatitis B acute flare. 
The serological and biochemical test results suggest that 
co-infection with HEV contributed to liver inflammation 
than HVB infection with no HEV or HCV co-infection28. 
To date, there are only eight recognized hepatitis B gen-
otypes, designated A to H29. However, as a result of  
whole gene sequencing, two additional genotypes that 
were proposed as I and J from Vietnam and Japan, re-
spectively, were later confirmed to be recombinant30-32. In 
this study, our Malaysian HBV isolates were found to be 
69.5% (57/82) genotype B and 30.5% (25/82) genotype 
C, which are the dominant genotypes in Southeast Asia33. 
Variations in clinical outcomes have been associated with 
hepatitis B genotypes, in which genotype C or D-infect-
ed patients have more severe outcomes than genotype A 
or B-infected patients34.  Hepatocellular carcinoma and 
liver cirrhosis are commonly diagnosed in patients in-
fected with HBV genotype C or D, more often than in 
those with genotype A or B35.  This concurs with our 
findings, since 17 of  the 25 genotype C-infected patients 
(68%) also had liver cirrhosis and all the three patients 
with HCC in this study were infected with genotype C 
(12%) viruses; the remaining 20% (5/25) genotype C-in-
fected patients were non-cirrhotic. In terms of  the thera-
peutic response, HBV genotype A- or B-infected patients 
responded better to interferon treatment than genotype 
C- or D-infected patients36.  Hepatitis B genotype B in 
this study was found to be associated with non-cirrhotic 
infections (68.4%) and acute flares (29.8%), with only one 
patient (1.8%) with liver cirrhosis. Hepatitis B e antigen 
seroconversion and seroclearance are significant events in 
the HBV natural history, with a projected yearly incidence 
of  2% and 12%, respectively37,38.  Earlier HBeAg sero-
conversion is associated with better outcomes and late or 
absent HBeAg seroconversion leads to faster progression 
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of  chronic hepatitis to cirrhosis after multiple hepatitis 
flares39. This is applicable to this study, as all our hepati-
tis B-infected cirrhotic patients were found to be HBeAg 
positive and the majority of  patients with an acute flare 
(94.1%) were also HBeAg positive, while the non-cir-
rhotic patients were HBeAg negative. Similarly, of  the 57 
genotype B-infected patients in this study, 64.9% were 
HBeAg negative and 35.1% were positive. Interestingly, 
92% genotype C-infected patients were HBeAg positive 
and 8% were negative, indicating lower HBeAg serocon-
version rates with genotype C compared to genotype B 
infection, supported by similar findings in previous stud-
ies40.
This study also revealed that the majority, i.e. 64.91% 
(37/57) of  HBV genotype B isolates belonged to the B2 
subtype and serotype adw2, while 12.28% (7/57) were of  
the B4 subtype and ayw1 serotype; the remaining 22.81% 
(13/57) belonged to the Ba subtype, serotype ayw. The 
geographical distribution of  these genotypes is similar to 
their sub-genotypes and has been shown to play a sig-
nificant role in clinical outcomes and anti-viral therapy 
outcomes41,42.  Hepatitis B genotype B is made up of  six 
sub-genotypes, B1 to B6, with B1 to B5 as the predom-
inant genotypes in East Asia; B1 is mainly found in Ja-
pan, while B6 is predominant in the Arctic region and 
has been associated with fulminant hepatitis and better 
responses to interferon treatment. 
Most hepatitis B genotype C isolates belonged to sub-
type C2, serotype ayr (88%), while the remaining 12% 
belonged to sub-type C4, serotype adrq. Genotype C was 
subdivided into four sub-genotypes (C1-C4)43, with C1 
as the major sub-type in East Asia, C2 in SouthEast Asia 
and China, C3 in Oceania and C4 in aborigines of  Austra-
lia44. An additional sub-genotype C5 was isolated in 2006 
in the Philippines45, and sub-genotype C6 was isolated 
from Papua in Indonesia and confirmed in 200946. At 
same time, another isolate was confirmed to be sub-gen-
otype C6 in the Philippines,47 and sub-genotype C7 was 
isolated in the Philippines and Indonesia48,49. The hepati-
tis C viruses in this study were found to be of  genotype 
3a, which has been reported to be globally distributed50 
and is thought to be associated with injectable drug use 
51. The Malaysian HEV isolates were found to be of  gen-
otype 4, which is a genotype exclusively found in Asia in 
both humans and domestic animals52,53.
Conclusion 
In this study, an insight was provided into the genetic dis-
tributions of  three hepatitis viruses (B, C and E) and the 
rate of  HBV co-infection with HCV and HEV among 
Malaysian chronic hepatitis B patients. Hepatitis B, gen-
otype C infection was found to be the most prevalent 
(68%) and was related to liver cirrhosis and HCC while, 
genotype B was found to be associated with non-cirrhotic 
infections (68.4%) and acute flares (29.8%). The rate of  
co-infection was found to be 9.8% for HBV and HEV 
and 1.2% for HBV and HCV; the remaining 89% of  pa-
tients were mono-infected. HCV superinfection present-
ed with hepatitis B acute flares. This co-infection played 
an important role in hepatitis B infection severity in terms 
of  morbidity and mortality. However, this study is not 
without limitation and some of  the limitations include; 
non-probability sampling techniques used in recruiting 
patients for this study, and insufficient clinical informa-
tion collected for this research limits it findings and con-
clusions from been generalized.
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